| Methods |
4‐ to 5‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 95‐110 mm Hg during 2 visits (days 22 and 29, or days 29 and 36), and two BP readings for two visits could not differ by > 8 mm Hg; 8‐week double‐blind treatment |
| Participants |
Irbesartan 150 mg: n=142(77 males,65 females); mean age=53.1(10.5) years; baseline sitting SBP=155.3(16.2) mm Hg, DBP=101.1(4.6) mm Hg;
Irbesartan 300 mg: n=140(80 males,60 females); mean age=55.6(10.4) years; baseline sitting SBP=155.4(16.0) mm Hg, DBP=100.4(4.5) mm Hg;
Losartan 100 mg: n=138(69 males,69 females); mean age=55.0(10.7) years; baseline sitting SBP=153.3(15.5) mm Hg, DBP=100.6(4.4) mm Hg;
Placebo: n=147(90 males,57 females); mean age=53.8(9.6) years; baseline sitting SBP=152.4(14.7) mm Hg, DBP=100.3(4.3) mm Hg |
| Interventions |
Irbesartan 150 mg once daily;
Irbesartan 300 mg once daily;
Losartan 100 mg once daily;
Placebo |
| Outcomes |
Adjusted mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SE of change reported, endpoint BP and SD not reported; baseline SD not reported, calculated SD from N and SE; BP data from Table 2, p. 448; Jadad score=4; funding source= Bristol‐Myers Squibb |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
